Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Conversion of Convertible Loan Notes

13 Jul 2015 14:57

RNS Number : 9047S
Flying Brands Limited
13 July 2015
 

Flying Brands Limited

Conversion of Convertible Loan Notes into Equity

 

The Directors of Flying Brands Limited (the "Company" or "Flying Brands") are pleased to announce that, Flare Capital Limited, has elected to convert its £25,000 convertible loan note, ('Convertible Loan Note'), together with accrued interest, into, in aggregate, 2,323,864 new units comprising one ordinary share of £0.01 each and one 'A' ordinary share ('Units') at the conversion price of £0.011 per Unit. In addition, Trevor Brown, a director of Flying Brands, has elected to convert £5,200 of Convertible Loan Notes, together with accrued interest, into, in aggregate, 483,364 Units. Following this conversion, Flying Brands has £269,800 Convertible Loan Notes outstanding. 

 

Further details of the Convertible Loan Notes were set out in the Company's announcement and circular, both dated 13 February 2015.

 

Total Voting Rights

 

Application has been made for the abovementioned 2,807,228 new Units to be admitted to trading on the standard listing segment of the Official List ('Admission'). Admission is expected to become effective and dealings to commence at 8.00 a.m. on 14 July 2015. On Admission, the Company will have 30,880,963 Units in issue.

 

The Company has no Units held in treasury. Accordingly the above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Following the conversion, Flare Capital Limited will be interested in 2,323,864 Units, representing approximately 7.53 per cent. of the Company's enlarged issued Unit share capital and Trevor Brown will be interested in 483,364 Units, representing approximately 1.57 per cent of the Company's enlarged issued Unit capital. 

 

 

End

 

The Directors of the Company are responsible for the contents of this announcement.

 

Enquiries:

 

Flying Brands Limited

Michael Murphy/Trevor Brown

Tel: 0207 469 0930

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRSFIFDDFISEIW
Date   Source Headline
27th May 20257:00 amRNSChange of Name
22nd May 20252:23 pmRNSResult of AGM
2nd May 20257:29 amRNSApplication: FDA Breakthrough Therapy Designation
29th Apr 202510:49 amRNSNotice of AGM
25th Apr 20251:46 pmRNSPublication of Annual Report
11th Apr 20253:32 pmRNSPromising Preliminary Results of Phase 1 Study
18th Mar 202510:38 amRNSPlacing to raise £250,000
3rd Feb 20257:00 amRNSIB Expands Distribution with Blackford
22nd Jan 20257:00 amRNSOperations Update
10th Jan 20257:49 amRNSIB and Prism Secure First Installation
20th Nov 20247:00 amRNSImaging Biometrics Expands Distribution
19th Nov 202411:27 amRNSBoard Changes
5th Nov 20247:00 amRNSNew Patent Application and Trading Update
15th Oct 202410:28 amRNSHolding(s) in Company
14th Oct 202412:08 pmRNSHolding(s) in Company
14th Oct 202412:05 pmRNSPDMR dealing and TR1 announcement
11th Oct 202410:42 amRNSAcquisition of Interest by Braveheart
25th Jun 20249:59 amRNSIB Opens Expanded Access Program
14th Jun 20248:38 amRNSClinical Trial Updates
29th May 20243:08 pmRNSResult of AGM
23rd May 20247:00 amRNSMajor East Coast Health System Chooses IB Nimble
20th May 20247:10 amRNSSecond FDA Rare Pediatric Disease Designation
17th May 20247:00 amRNSIB Software Enhances Clinical Decision-Making
10th May 20248:15 amRNSRare Pediatric Disease Designation Granted to GaM
2nd May 202412:47 pmRNSIB Announces Expanded Access Program for GaM
29th Apr 20243:26 pmRNSPublication of Annual Report
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.